Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access               Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain SUPN message board posts where the ticker symbol SUPN has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest SUPN SEC Filings

Filings Format Description Filing Date File/Film Number
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001104659-18-067217 (34 Act)  Size: 8 MB
2018-11-09 001-35518
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001104659-18-066998 (34 Act)  Size: 43 KB
2018-11-08 001-35518
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001104659-18-066367 (34 Act)  Size: 252 KB
2018-11-06 001-35518
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001104659-18-063964 (34 Act)  Size: 44 KB
2018-10-25 001-35518
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001104659-18-057845 (34 Act)  Size: 42 KB
2018-09-21 001-35518
8-K  Documents Current report, items 1.01, 8.01, and 9.01
Acc-no: 0001104659-18-057416 (34 Act)  Size: 59 KB
2018-09-18 001-35518
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001104659-18-055660 (34 Act)  Size: 47 KB
2018-09-07 001-35518
8-K  Documents Current report, items 7.01, 8.01, and 9.01
Acc-no: 0001104659-18-055089 (34 Act)  Size: 58 KB
2018-09-04 001-35518
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001104659-18-050920 (34 Act)  Size: 6 MB
2018-08-09 001-35518
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001104659-18-050207 (34 Act)  Size: 266 KB
2018-08-07 001-35518
More SUPN SEC Filings

Related news from
Tue, 20 Nov 2018
13:05:09 +0000
See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
Short interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
Thu, 15 Nov 2018
16:06:32 +0000
What Should Investors Know About Supernus Pharmaceuticals Inc’s (NASDAQ:SUPN) Future?
After Supernus Pharmaceuticals Inc’s (NASDAQ:SUPN) earnings announcement on 30 September 2018, analysts seem fairly confident, as a 28% increase in profits is expected in the upcoming year, though this is<div><a class="permalink" href="">Read More...</a></div>
Tue, 13 Nov 2018
17:13:50 +0000
5 Sizzling Small-Cap Stocks to Buy Today
Small-cap stocks have long beaten their larger rivals in the returns department. For starters, there’s plenty of growth to be had in small-cap stocks. Secondly, thanks to their domestic focus, small-cap stocks directly benefit more from the rising U.S. economy and the Republican tax plan.
Wed, 07 Nov 2018
21:39:07 +0000
Supernus to Present at Three November Healthcare Conferences
ROCKVILLE, Md., Nov. 07, 2018 -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of.
Wed, 07 Nov 2018
20:50:30 +0000
Edited Transcript of SUPN earnings conference call or presentation 7-Nov-18 2:00pm GMT
Q3 2018 Supernus Pharmaceuticals Inc Earnings Call
Wed, 07 Nov 2018
13:24:00 +0000
3 Top Biotech Stocks to Buy in November
If you don't consider adding these biotech stocks to your portfolio this month, you could wind up missing out on an opportunity.
Wed, 07 Nov 2018
00:35:12 +0000
Supernus Pharmaceuticals (SUPN) Tops Q3 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of 20.93% and 2.40%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Tue, 06 Nov 2018
23:32:24 +0000
Supernus: 3Q Earnings Snapshot
The Rockville, Maryland-based company said it had profit of 52 cents per share. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research ...
Tue, 06 Nov 2018
21:15:00 +0000
Supernus Announces Third Quarter 2018 Financial Results and Record Quarterly Revenue
Total revenue of $103.0 million, a 28% increase over 2017Net product sales of $100.2 million, a 28% increase over 2017Operating earnings of $37.5 million, a 68% increase over.
Fri, 26 Oct 2018
12:25:00 +0000
Recent Analysis Shows Supernus Pharmaceuticals, GDS HOLDINGS, Golden Ocean Group, Golar LNG, Endo International plc, and 51job Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Oct. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Wed, 24 Oct 2018
20:30:00 +0000
Supernus to Host Third Quarter 2018 Earnings Conference Call
ROCKVILLE, Md., Oct. 24, 2018 -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the.
Mon, 15 Oct 2018
12:15:12 +0000
Supernus Pharmaceuticals (SUPN): Moving Average Crossover Alert
Supernus Pharmaceuticals, Inc. (SUPN) could be a stock to avoid from a technical perspective
Wed, 10 Oct 2018
09:17:09 +0000
New Strong Sell Stocks for October 10th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Fri, 21 Sep 2018
19:52:05 +0000
Did Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Create Value For Shareholders?
This analysis is intended to introduce important early concepts to people who are starting to invest and want to learn about Return on Equity using a real-life example. Supernus PharmaceuticalsRead More...
Thu, 20 Sep 2018
21:28:54 +0000
Supernus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
ROCKVILLE, Md., Sept. 20, 2018-- Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, ...
Fri, 14 Sep 2018
12:38:09 +0000
The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut
A roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 13.) Abbott Laboratories (NYSE: ABT ) Baxter International Inc ...
Thu, 13 Sep 2018
20:15:00 +0000
Supernus to Acquire Biscayne Neurotherapeutics
Supernus Pharmaceuticals, Inc. (SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it entered into a merger agreement to acquire Biscayne Neurotherapeutics (Biscayne), a privately-held company developing a novel treatment for epilepsy. Supernus will obtain worldwide rights (excluding certain markets in Asia where rights have been out-licensed) to Biscayne’s product candidate that is in Phase I clinical development and that has received an Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of Dravet Syndrome, a severe form of childhood epilepsy.
Thu, 13 Sep 2018
13:02:45 +0000
SUPN’s Product Portfolio and Financial Guidance
Supernus Pharmaceuticals’ (SUPN) Trokendi XR generated revenues of $76.4 million in the second quarter, compared to $56.0 million in the second quarter of 2017, reflecting ~36.4% YoY (year-over-year) growth.

"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This site is a gem, and based on the posts by many members and my personal experience it is a site for learning, sharing and especially making money." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards